Skip to main content

Table 2 Primary outcome result of BMD change (%)**

From: Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis

BMD change (%)

No. of groups

Participants

Evidence synthesis

I2

P value

Egger's test

GRADE

Abaloparatide versus Placebo

24 weeks

Lumbar spine

8

2280

WMD 3.64 [1.84, 5.44]

97%

P < 0.00001*

P < 0.0001*

Very Low

Fem neck

4

1911

WMD 1.85 [1.83, 1.87]

0%

P < 0.00001*

P = 0.0003*

Low

Total hip

8

2280

WMD 1.65 [1.36, 1.93]

21%

P < 0.00001*

P < 0.0001*

Low

48 weeks#

Lumbar spine

1

1645

WMD 9.32 [9.28, 9.36]

N/A

P < 0.00001*

N/A

Low

Fem neck

1

1645

WMD 3.06 [3.04, 3.08]

N/A

P < 0.00001*

N/A

Low

Total hip

1

1645

WMD 3.32 [3.30, 3.34]

N/A

P < 0.00001*

N/A

Low

Abaloparatide versus Teriparatide

24 weeks

Lumbar spine

3

266

WMD -0.61 [− 2.89, 1.68]

83%

P = 0.60

P = 0.0007*

Very Low

Fem neck

3

266

WMD 1.58 [0.52, 2.63]

0%

P = 0.003*

P = 0.8685

High

Total hip

3

266

WMD 1.46 [0.59, 2.32]

0%

P = 0.0009*

P = 0.5417

High

48 weeks#

Lumbar spine

1

1642

WMD 1.49 [1.45, 1.53]

N/A

P < 0.00001*

N/A

Low

Fem neck

1

1642

WMD 1.11 [1.08, 1.14]

N/A

P < 0.00001*

N/A

Low

Total hip

1

1642

WMD 1.12 [1.10, 1.14]

N/A

P < 0.00001*

N/A

Low

  1. Bold indicates a high level of confidence in the data
  2. #Only "Miller 2016" (NCT01343004) has results for BMD change (%) at 48th week, which was administered as 80 μg of abaloparatide by daily injection
  3. *These P values are less than or equal to 0.05
  4. **The funnel plots are in the Additional file 1: Appendix 8